Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Who Took Part

The study group was 11 patients.

By PubMed's age tags, the people studied were young children, children and adults, both men and women.

The researchers carried out a follow-up analysis of a randomized controlled open-label GH study in short prepubertal children with XLH on phosphate and active vitamin D treatment.

The changes in SD scores (SDS) of height, sitting height, leg and arm length, and sitting height index (i.e., the ratio between sitting height and height) were analyzed in 11 out of 16 patients followed-up until adult height.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the patients and staff both knew the treatment.

What Was Measured

The subject headings attached to it are Anthropometry, Body Height, Dwarfism, Familial Hypophosphatemic Rickets and Human Growth Hormone.

The authors tagged it with the keywords Adult height, Disproportion, Growth hormone treatment, Sitting height index and X-linked hypophosphatemic rickets.

What This Means in Plain Language

The paper is a randomized and open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 11 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Pediatric nephrology (Berlin, Germany)), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.